← Leaderboards
Karen M Mann
H. Lee Moffitt Cancer Ctr & Res Inst
$1,370,948
Attributed
$1,370,948
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $469.1K · FY2023–25$500K$375K$250K$125K$0
'23
'24
'25
Funding mix
By agency
NIH$1,370,948 · 1
By mechanism
R01$1,370,948 · 1
Top collaborators
No co-investigators on record.
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Jiandong Chen$17,685,452
- Gary W Daughdrill$4,606,610
- Jhanelle E. Gray$250,326
- Min-Jeong Yang$486,650
- Kimberley T Lee$853,846
Others in their field
Other Rising Stars on “Antisense Oligonucleotides”
- Karen Sachs · Modulo Bio, Inc.$2,885,988
- Zhihua Feng · Acurastem, Inc.$2,782,758
- Qin Liu · Massachusetts Eye And Ear Infirmary$2,373,472
- Wen Shen · Lucerna, Inc.$1,728,231
- Seiko Ikezu · Mayo Clinic Jacksonville$1,632,295
- Ricardo Mouro Pinto · Massachusetts General Hospital$1,596,958
Research focus
Antisense OligonucleotidesAutomobile DrivingBiologicalBiological ProcessCancer Cell DifferentiationCancer CenterCancer ControlCancer InitiationCancer RecurrenceCancer Stem CellCell Differentiation ProcessCell GrowthCell LineCell MotilityCellsCohortComplementary DnaCoupledCrosslinking And Immunoprecipitation SequencingDefined ContributionDiagnosisDifferentiation AntigensDisease OutcomeAlternative Splicing
Grant awards (3)
RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing$461,101
R01 · FY2025 · CA · contact PI
RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing$440,712
R01 · FY2024 · CA · contact PI
RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing$469,135
R01 · FY2023 · CA · contact PI